| Literature DB >> 32977400 |
María Pedrosa-Rivera1, Javier Praena1, Ignacio Porras1, Manuel P Sabariego1, Ulli Köster2, Michael Haertlein2,3, V Trevor Forsyth2,3,4, José C Ramírez5, Clara Jover5, Daniel Jimena5, Juan L Osorio5, Patricia Álvarez6, Carmen Ruiz-Ruiz6, María J Ruiz-Magaña6.
Abstract
The experimental determination of the relative biological effectiveness of thermal neutron factors is fundamental in Boron Neutron Capture Therapy. The present values have been obtained while using mixed beams that consist of both neutrons and photons of various energies. A common weighting factor has been used for both thermal and fast neutron doses, although such an approach has been questioned. At the nuclear reactor of the Institut Laue-Langevin a pure low-energy neutron beam has been used to determine thermal neutron relative biological effectiveness factors. Different cancer cell lines, which correspond to glioblastoma, melanoma, and head and neck squamous cell carcinoma, and non-tumor cell lines (lung fibroblast and embryonic kidney), have been irradiated while using an experimental arrangement designed to minimize neutron-induced secondary gamma radiation. Additionally, the cells were irradiated with photons at a medical linear accelerator, providing reference data for comparison with that from neutron irradiation. The survival and proliferation were studied after irradiation, yielding the Relative Biological Effectiveness that corresponds to the damage of thermal neutrons for the different tissue types.Entities:
Keywords: boron neutron capture therapy; relative biological effectiveness; thermal neutrons
Mesh:
Year: 2020 PMID: 32977400 PMCID: PMC7598166 DOI: 10.3390/cells9102144
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Simulated neutron spectrum at the end of the collimation system of the PF1B line at the Institut Laue-Langevin (ILL) (squares) when compared with neutron Boron Neutron Capture Therapy (BNCT) sources [17,18], such as the epithermal beam of Brookhaven Medical Research Reactor (BMRR), epithermal and thermal beams of Kyoto University Research Reactor Institute (KURR) and the epithermal beam in Finland Reactor 1 (FIR1). Data are expressed in neutron flux per unit of lethargy.
Figure 2Picture and schematic cut view of the experimental arrangement installed on the PF1B instrument at the institute Laue-Langevin (ILL). Two cuvettes containing cells were irradiated at the same time. All of the cells are irradiated homogeneously and the second cuvette receives a smaller dose than the first one. LiF is used as the first layer of collimators and as a beam stop, capturing neutrons without the generation of secondary gamma radiation.
Figure 3Experimental arrangements for cell irradiations with photons used at the medical linear accelerator in Granada. Two flasks with a layer of cells are irradiated at the same time with the same dose.
Nitrogen content and dose components of the cell lines irradiated using the PF1B neutron beam instrument at the Institut Laue-Langevin (ILL). Campaign of June 2018.
| Cell Line | Nitrogen Content (%) | Thermal Dose, | Gamma Dose, | ||
|---|---|---|---|---|---|
| Cuvette 1 | Cuvette 2 | Cuvette 1 | Cuvette 2 | ||
| A375 | 2.2 | 0.026 | 0.012 | 0.013 | 0.010 |
| Cal33 | 2.3 | 0.024 | 0.011 | 0.013 | 0.010 |
| U87 | 2.0 | 0.021 | 0.010 | 0.013 | 0.010 |
| SQ20 | 2.3 | 0.024 | 0.011 | 0.013 | 0.010 |
| HEK293 | 1.7 | 0.018 | 0.008 | 0.013 | 0.010 |
| MRC5 | 1.0 | 0.011 | 0.005 | 0.013 | 0.010 |
Figure 4A375 plates for both clonogenic and proliferative assays. Left, plate for clonogenic assay with the control sample (CT) and the sample irradiated with a neutron dose of 4 Gy at day seven after irradiation. Right, BrdU cell proliferation assay of control and irradiated cells at day four after irradiation. The samples were analyzed in triplicate for each data point.
Figure 5Proliferation and survival data for the different cell lines in response to neutron irradiation. Proliferation (expressed as absorbance relative to control (CT), as determined by BrdU assay), and survival (based on clonogenic assays) are represented for each cell line as a function of the total absorbed dose after neutron irradiation at ILL. Data were obtained from between two and four individual experiments with three replicate dishes plated per point per experiment.
Figure 6Clonogenic survival of six cell lines as a function of the absorbed dose (Gy) following irradiation with photons at the medical linear accelerator, S, with neutrons at the ILL beam, S, and, derived, ILL neutrons alone, S. S for U87 from [27] and S for SQ20 from the one obtained for Cal33. The data were obtained from between two and seven individual experiments after photon irradiation and neutron irradiation. Cells were seeded in triplicate for each data point in each experiment.
Alpha and beta values (±standard error) for medical linear accelerator irradiations and for the different dose components at ILL.
| Cell Line | ILL, Total | Medical LINAC, Photons | ILL, Pure Neutrons | ||
|---|---|---|---|---|---|
| αILL (Gy−1) | βILL (Gy−2) | αγ (Gy−1) | βγ (Gy−1) | αn (Gy−1) | |
| A375 | 1.22 ± 0.16 | 0.04 ± 0.06 | 0.25 ± 0.03 | 0.075 ± 0.012 | 1.86 ± 0.06 |
| Cal33 | 0.56 ± 0.09 | 0.21 ± 0.04 | 0.03 ± 0.02 | 0.047 ± 0.007 | 1.65 ± 0.05 |
| U87 | 0.98 ± 0.43 | 0.07 ± 0.21 | 0.23 ± 0.02 | 0.012 ± 0.005 | 1.74 ± 0.19 |
| SQ20 | 0.44 ± 0.27 | 0.31 ± 0.13 | 0.03 ± 0.02 | 0.047 ± 0.007 | 1.63 ± 0.13 |
| HEK293 | 1.18 ± 0.10 | 0.14 ± 0.06 | 0.16 ± 0.01 | 0.091 ± 0.002 | 2.37 ± 0.09 |
| MRC5 | 1.41 ± 0.50 | 0.00 ± 0.50 | 0.34 ± 0.08 | 0.011 ± 0.015 | 3.40 ± 0.45 |
Thermal neutron relative biological effectiveness (RBE) values (w factor) for the different cell lines irradiated at ILL as a function of the cell survival fraction.
| Survival | A375 | Cal33 | U87 | SQ20 | HEK293 | MRC5 |
|---|---|---|---|---|---|---|
| 50% | 4.8 ± 0.7 | 8.4 ± 1.3 | 6.7 ± 2.6 | 8.4 ± 1.7 | 6.8 ± 0.4 | 9.5 ± 9.8 |
| 37% | 4.3 ± 0.7 | 7.1 ± 1.2 | 6.4 ± 2.7 | 7.1 ± 1.5 | 6.0 ± 0.4 | 9.3 ± 11.0 |
| 10% | 3.3 ± 0.6 | 4.8 ± 0.8 | 5.5 ± 5.6 | 4.8 ± 1.1 | 4.3 ± 0.3 | 8.5 ± 11.8 |
| 1% | 2.6 ± 0.5 | 3.4 ± 0.6 | 4.6 ± 2.3 | 3.4 ± 0.8 | 3.2 ± 0.2 | 7.6 ± 11.0 |
Constant weighting factors, W, of the simplified iso-effective formalism [7].
| Weighting Factor | A375 | Cal33 | U87 | SQ20 | HEK293 | MRC5 |
|---|---|---|---|---|---|---|
|
| 7.3 ± 1.2 | 57 ± 51 | 7.7 ± 1.6 | 57 ± 51 | 14.5 ± 1.2 | 10 ± 4 |